The latest biotech news

News and Trends 4 May 2021

Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe

Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo in Germany after a pricing dispute with health authorities — a blow that could have repercussions for the rollout of other gene therapies in Europe. Zynteglo was approved in the EU in 2019 as the first-ever gene therapy for the […]

May 4, 2021 - 5 minutesmins - By Anita Chakraverty

medical cancer checkpoint inhibitor immunotherapy

News and Trends 29 Apr 2021

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […]

April 29, 2021 - 5 minutesmins - By Mark Zipkin

multiple sclerosis novartis roche ema approval

News and Trends 27 Apr 2021

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […]

April 27, 2021 - 6 minutesmins - By Jonathan Smith

cardiovascular disease amarin vascepa vazkepa

News and Trends 21 Apr 2021

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Last month’s EU approval of Vazkepa — a treatment derived from fish oil and branded as Vascepa in the US — has added much-needed ammunition to the arsenal of doctors battling cardiovascular disease. Yet other similar treatments are returning lukewarm results and the possibility of approvals being withdrawn hangs in the air. Icosapent ethyl, a […]

April 21, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 20 Apr 2021

Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions

The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market. Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics […]

April 20, 2021 - 5 minutesmins - By Anita Chakraverty

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

peanut allergy treatment DBV Technologies Aimmune Viaskin Palforzia

News and Trends 14 Apr 2021

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market

Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a comeback plan that could carve it a niche in the peanut allergy treatment market. The French biotech firm DBV is coming back from a snub by […]

April 14, 2021 - 5 minutesmins - By External Contributor

News and Trends 1 Apr 2021

Have European Investors Missed the Exosome ‘Gold Rush’?

When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled that investors are taking exosome therapies seriously. But a lack of European investors in the exosome field raises the very real possibility that the best opportunities have already passed, along with the chance to build an exosome ecosystem to rival […]

April 1, 2021 - 5 minutesmins - By Mark Zipkin

VC finance stock funds ipo gamma delta t cell lava therapeutics

News and Trends 31 Mar 2021

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with an €85.6M ($100.5M) IPO. This is a sign of mounting investor interest in cancer treatments based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s […]

March 31, 2021 - 5 minutesmins - By Anita Chakraverty

News and Trends 25 Mar 2021

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in other fields like cancer or gene therapy. However, complex challenges remain, such as circumventing immunity to adenoviral treatments. Earlier this month, Johnson & Johnson’s candidate became the first single-shot Covid-19 vaccine to get the EMA green light. The vaccine is […]

March 25, 2021 - 6 minutesmins - By Victor Kotsev

meat alternatives solar foods impossible foods

News and Trends 24 Mar 2021

Global Funding for Meat Alternative Companies Tripled in 2020

Companies developing sustainable meat and dairy alternatives smashed records with a €2.6B ($3.1B) haul last year. Why has it been such a bumper harvest? Traditional agriculture is a major polluter, especially in the case of meat production. The highest estimations place its share of global greenhouse gas emissions at up to 20%. In an effort […]

March 24, 2021 - 7 minutesmins - By Jonathan Smith

News and Trends 18 Mar 2021

Europe Falls Behind in Efforts to Track Covid-19 Variants

As barely a third of European countries meet targets to track concerning Covid-19 variants, diagnostics and genomics companies are scrambling to help them tackle this challenge. New strains of the Covid-19 coronavirus are sweeping Europe as vaccine distribution efforts roll on. These variants often gain traction when mutations let them become more virulent or spread […]

March 18, 2021 - 5 minutesmins - By Anita Chakraverty

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe

BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market

Have European Investors Missed the Exosome ‘Gold Rush’?

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

Global Funding for Meat Alternative Companies Tripled in 2020

Europe Falls Behind in Efforts to Track Covid-19 Variants

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!